

${\sf GSK_HR_2022_EFPIA_HCPO_Methodological_Note_-V80@=}$

Term	Definition
Corporate scope	GSK will issue one report for each country showing all Transfers of Value made to HCPs /
	HCOs in that country by GSK and by ViiV Healthcare.
Reporting date	GSK has defined two types of Transfers of Value for Reporting Date purposes:
	- a Monetary Transfer of Value is a payment of money made to an HCP/HCO by GSK
	either directly or through an intermediary (for example, fees for service). The Reporting
	Date for these Transfers of Value will be the actual payment date, irrespective of when
	the event happened (for example, when a consultancy fee is paid, not when the work
	took place).
	- a Non-monetary Transfer of Value is a benefit received from GSK either directly or
	through an intermediary without a monetary payment (a flight or a congress registration
	fee paid to a travel agent or events organiser, for example). The Reporting Date for these
	Transfers of Value will be the event date (for example, when the congress took place).
Value Added Tax	GSK has taken the decision to report values including VAT wherever possible due to the
	complexity of VAT regimes around Europe and the inconsistency of whether VAT may or
	may not be reimbursable depending on where the transaction took place and the country
	of residency of the HCPor HCO. All other taxes are included in the reported values
Currency	GSK records Transfers of Value in the currency in which the transaction took place. The
conversions	report will show all values in the currency of the country in which the report is made.
HCPs employed by	GSK will not report payments made to HCPs who are employed by GSK as staff members.
GSK	GSK considers that it would be inappropriate to the disclose an employee's salary, bonus,
	expenses and benefits.
Distributors	If a distributor is involved in the promotion of medicines on behalf of a Member
	Company in an EFPIA country, and is therefore under the operational control and
	guidance of that Member Company, then its activities are reportable by the Member
	Company in that country.
	In such cases GSK will provide the data as a standalone distributor report (using the
	structure set out in Schedule 2 of the EFPIA Code), based on the distributor's own
	methodology and policies.
Multi-year	Transfers of Value are reported on the relevant Reporting Date (payment date or event
contracts	date – see above) irrespective of the duration of the contract.

A distributor PHOENIX Farmacija d.o.o (Phoenix) is involved in the promotion of medicines on behalf of GSK in Croatia, and is therefore under the operational control and guidance of GSK; its activities are reportable by GSK, to report Transfers of Value made to HCPs / HCOs in Croatia by Phoenix, GSK and by ViiV Healthcare.